Membrane-perturbing effect of fatty acids and lysolipids

Mouritsen, 2005 Simons, 2011 Blume, 2004, Lipids, 60 Singer, 1972, The fluid mosaic model of the structure of cell membranes, Science, 175, 720, 10.1126/science.175.4023.720 Bagatolli, 2010, An outlook on organization of lipids in membranes: searching for a realistic connection with the organization of biological membranes, Prog Lipid Res, 49, 378, 10.1016/j.plipres.2010.05.001 Engelman, 2005, Membranes are more mosaic than fluid, Nature, 438, 578, 10.1038/nature04394 Matsumoto, 2006, Lipid domains in bacterial membranes, Mol Microbiol, 61, 1110, 10.1111/j.1365-2958.2006.05317.x Quinn, 2010, A lipid matrix model of membrane raft structure, Prog Lipid Res, 49, 390, 10.1016/j.plipres.2010.05.002 Zhang, 2008, Membrane lipid homeostasis in bacteria, Nat Rev Microbiol, 6, 222, 10.1038/nrmicro1839 Quinn, 2012, Lipid–lipid interactions in bilayer membranes: married couples and casual liaisons, Prog Lipid Res, 51, 179, 10.1016/j.plipres.2012.01.001 Phillips, 2009, Emerging roles for lipids in shaping membrane-protein function, Nature, 459, 379, 10.1038/nature08147 Sanderson, 2005, Peptide–lipid interactions: insights and perspectives, Org Biomol Chem, 3, 201, 10.1039/B415499A Brogden, 2005, Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?, Nat Rev Microbiol, 3, 238, 10.1038/nrmicro1098 Chen, 2012, Accumulation of an antidepressant in vesiculogenic membranes of yeast cells triggers autophagy, PLoS One, 7, e34024, 10.1371/journal.pone.0034024 Heimburg, 2007, The thermodynamics of general anesthesia, Biophys J, 92, 3159, 10.1529/biophysj.106.099754 Perez-Gil, 2008, BBA special issue: protein modulation of membrane structure, Biochim Biophys Acta, 1778, 1527, 10.1016/j.bbamem.2008.06.001 Mouritsen, 2011, Model answers to lipid membrane questions, Cold Spring Harb Perspect Biol, 3, a004622, 10.1101/cshperspect.a004622 Arouri, 2009, Peptide induced demixing in PG/PE lipid mixtures: a mechanism for the specificity of antimicrobial peptides towards bacterial membranes?, Biochim Biophys Acta, 1788, 650, 10.1016/j.bbamem.2008.11.022 Arouri, 2011, Morphological changes induced by the action of antimicrobial peptides on supported lipid bilayers, J Phys Chem B, 115, 158, 10.1021/jp107577k Lohner, 2008, Liposome-based biomembrane mimetic systems: implications for lipid–peptide interactions, Adv Planar Lipid Bilayers Liposomes, 6, 103, 10.1016/S1554-4516(07)06005-X Farsad, 2003, Mechanisms of membrane deformation, Curr Opin Cell Biol, 15, 372, 10.1016/S0955-0674(03)00073-5 Itoh, 2009, Mechanisms of membrane deformation by lipid-binding domains, Prog Lipid Res, 48, 298, 10.1016/j.plipres.2009.05.002 McMahon, 2005, Membrane curvature and mechanisms of dynamic cell membrane remodelling, Nature, 438, 590, 10.1038/nature04396 Zimmerberg, 2006, How proteins produce cellular membrane curvature, Nat Rev Mol Cell Biol, 7, 9, 10.1038/nrm1784 Tamm, 2012, Comprehensive biophysics Tamm, 2005 Barenholz, 2001, Liposome application: problems and prospects, Curr Opin Colloid Interface Sci, 6, 66, 10.1016/S1359-0294(00)00090-X Fenske, 2008, Liposomal nanomedicines, Expert Opin Drug Deliv, 5, 25, 10.1517/17425247.5.1.25 Storm, 1998, Liposomes: quo vadis?, Pharm Sci Technol Today, 1, 19, 10.1016/S1461-5347(98)00007-8 Fricker, 2010, Phospholipids and lipid-based formulations in oral drug delivery, Pharm Res, 27, 1469, 10.1007/s11095-010-0130-x Hillaireau, 2009, Nanocarriers’ entry into the cell: relevance to drug delivery, Cell Mol Life Sci, 66, 2873, 10.1007/s00018-009-0053-z Harush-Frenkel, 2008, Nanoparticle–cell interactions: drug delivery implications, Crit Rev Ther Drug Carrier Syst, 25, 485, 10.1615/CritRevTherDrugCarrierSyst.v25.i6.10 Bray, 2012, Global cancer transitions according to the human development index (2008–2030): a population-based study, Lancet Oncol, 13, 790, 10.1016/S1470-2045(12)70211-5 Kaasgaard, 2010, Liposomal cancer therapy: exploiting tumor characteristics, Expert Opin Drug Deliv, 7, 225, 10.1517/17425240903427940 Das, 2009, Ligand-based targeted therapy for cancer tissue, Expert Opin Drug Deliv, 6, 285, 10.1517/17425240902780166 Malam, 2009, Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer, Trends Pharmacol Sci, 30, 592, 10.1016/j.tips.2009.08.004 You, 2010, Bioresponsive matrices in drug delivery, J Biol Eng, 4, 15, 10.1186/1754-1611-4-15 Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387 Andresen, 2005, Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release, Prog Lipid Res, 44, 68, 10.1016/j.plipres.2004.12.001 Landon, 2011, Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer, Open Nanomed J, 3, 38, 10.2174/1875933501103010038 Arouri, 2012, Phospholipase A2-susceptible liposomes of anticancer double lipid-prodrugs, Eur J Pharm Sci, 45, 408, 10.1016/j.ejps.2011.09.013 Schroeder, 2009, Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes, Chem Phys Lipids, 162, 1, 10.1016/j.chemphyslip.2009.08.003 Preiss, 2011, Stimuli–responsive liposome-nanoparticle assemblies, Expert Opin Drug Deliv, 8, 1025, 10.1517/17425247.2011.584868 Mouritsen, 2011, Lipids, curvature, and nano-medicine, Eur J Lipid Sci Technol, 113, 1174, 10.1002/ejlt.201100050 Burke, 2009, Phospholipase A2 structure/function, mechanism, and signaling, J Lipid Res, 50, S237, 10.1194/jlr.R800033-JLR200 Murakami, 2011, Recent progress in phospholipase A(2) research: from cells to animals to humans, Prog Lipid Res, 50, 152, 10.1016/j.plipres.2010.12.001 Six, 2000, The expanding superfamily of phospholipase A2 enzymes: classification and characterization, Biochim Biophys Acta, 1488, 1, 10.1016/S1388-1981(00)00105-0 Kudo, 2004, Diversity of phospholipase A2 enzymes, Biol Pharm Bull, 27, 1158 Murakami, 2003, New phospholipase A(2) isozymes with a potential role in atherosclerosis, Curr Opin Lipidol, 14, 431, 10.1097/00041433-200310000-00003 Hui, 2012, Phospholipase A(2) enzymes in metabolic and cardiovascular diseases, Curr Opin Lipidol, 23, 235, 10.1097/MOL.0b013e328351b439 Tselepis, 2002, Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase, Atherosclerosis (Suppl), 3, 57, 10.1016/S1567-5688(02)00045-4 Murata, 1993, Expression of group-II phospholipase A2 in malignant and non-malignant human gastric mucosa, Br J Cancer, 68, 103, 10.1038/bjc.1993.294 Tribler, 2007, Increased expression and activity of group IIA and X secretory phospholipase A2 in peritumoral versus central colon carcinoma tissue, Anticancer Res, 27, 3179 Scott, 2010, Emerging roles for phospholipase A2 enzymes in cancer, Biochimie, 92, 601, 10.1016/j.biochi.2010.03.019 Hu, 2011, Cytosolic phospholipase A(2) and its role in cancer, Clin Oncol Cancer Res, 8, 71, 10.1007/s11805-011-0562-z Belinsky, 2007, Expression of secretory phospholipase A2 in colon tumor cells potentiates tumor growth, Mol Carcinog, 46, 106, 10.1002/mc.20271 Cai, 2012, Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer, FASEB J, 26, 3306, 10.1096/fj.12-207597 Tosato, 2010, Cytosolic phospholipase A2(alpha) and cancer: a role in tumor angiogenesis, J Natl Cancer Inst, 102, 1377, 10.1093/jnci/djq324 Yano, 2011, Group V secretory phospholipase A2 plays a pathogenic role in myocardial ischaemia-reperfusion injury, Cardiovasc Res, 90, 335, 10.1093/cvr/cvq399 Wright, 2009, Inflammatory biomarkers of vascular risk as correlates of leukoariosis, Stroke, 40, 3466, 10.1161/STROKEAHA.109.559567 Mouritsen, 2006, Activation of interfacial enzymes at membrane surfaces, J Phys: Condens Matter, 18, 1293, 10.1088/0953-8984/18/28/S12 Pedersen, 2010, Liposomal formulation of retinoids designed for enzyme triggered release, J Med Chem, 53, 3782, 10.1021/jm100190c de Jonge, 2010, Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation, Eur J Cancer, 46, 3016, 10.1016/j.ejca.2010.07.015 Davidsen, 2003, Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue, Biochim Biophys Acta, 1609, 95, 10.1016/S0005-2736(02)00659-4 Davidsen, 2002, Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes, Biochim Biophys Acta, 1564, 256, 10.1016/S0005-2736(02)00461-3 Jespersen, 2012, Lipids, curvature stress, and the action of lipid prodrugs: free fatty acids and lysolipid enhancement of drug transport across liposomal membranes, Biochimie, 94, 2, 10.1016/j.biochi.2011.07.029 Rasmussen, 2010, Effect of free fatty acids and lysolipids on cellular uptake of doxorubicin in human breast cancer cell lines, Anticancer Drugs, 21, 674, 10.1097/CAD.0b013e32833c2cf7 Hoyrup, 2001, Lipid membrane partitioning of lysolipids and fatty acids: effects of membrane phase structure and detergent chain lengths, J Phys Chem B, 105, 2649, 10.1021/jp003631o Grit, 1992, The effect of aging on the physical stability of liposome dispersions, Chem Phys Lipids, 62, 113, 10.1016/0009-3084(92)90089-8 Jain, 1981, Structure of 1-acyl lysophosphatidylcholine and fatty acid complex in bilayers, Biochim Biophys Acta, 642, 203, 10.1016/0005-2736(81)90150-4 Jain, 1980, Association of lysophosphatidylcholine with fatty acids in aqueous phase to form bilayers, Nature, 284, 486, 10.1038/284486a0 Inoue, 1974, Effect of exogenous lysolecithin on liposomal membranes its relation to membrane fluidity, Biochim Biophys Acta, 363, 361, 10.1016/0005-2736(74)90075-3 McKersie, 1989, Free fatty-acid effects on leakage, phase properties and fusion of fully hydrated model membranes, Biochim Biophys Acta, 982, 156, 10.1016/0005-2736(89)90186-7 Van Echteld, 1981, Effects of lysophosphatidylcholines on phosphatidylcholine and phosphatidylcholine/cholesterol liposome systems as revealed by 31P-NMR, electron microscopy and permeability studies, Biochim Biophys Acta, 649, 211, 10.1016/0005-2736(81)90408-9 Agafonov, 2003, A permeability transition in liposomes induced by the formation of Ca2+/palmitic acid complexes, Biochim Biophys Acta, 1609, 153, 10.1016/S0005-2736(02)00666-1 Mironova, 2001, Palmitic and stearic acids bind Ca2+ with high affinity and form nonspecific channels in black-lipid membranes. Possible relation to Ca2+-activated mitochondrial pores, J Bioenerg Biomembr, 33, 319, 10.1023/A:1010659323937 Mouritsen, 2010, The liquid-ordered state comes of age, Biochim Biophys Acta, 1798, 1286, 10.1016/j.bbamem.2010.02.017 Bhamidipati, 1995, Interactions of lyso 1-palmitoylphosphatidylcholine with phospholipids: a 13C and 31P NMR study, Biochemistry, 34, 5666, 10.1021/bi00016a043 Kumar, 1989, Lysophosphatidylcholine stabilizes small unilamellar phosphatidylcholine vesicles. Phosphorus-31 NMR evidence for the “wedge” effect, Biophys J, 55, 789, 10.1016/S0006-3495(89)82877-2 Mabrey, 1977, Incorporation of saturated fatty acids into phosphatidylcholine bilayers, Biochim Biophys Acta, 486, 444, 10.1016/0005-2760(77)90094-7 Sandstrom, 2005, Effects of lipid segregation and lysolipid dissociation on drug release from thermosensitive liposomes, J Controlled Release, 107, 131, 10.1016/j.jconrel.2005.06.001 Phoeung, 2010, PH-triggered release from nonphospholipid LUVs modulated by the pKa of the included fatty acid, Langmuir, 26, 12769, 10.1021/la1014829 Rosholm, 2012, Characterization of fluorinated catansomes: a promising vector in drug-delivery, Langmuir, 28, 2773, 10.1021/la2039834 Mukerjee, 1971, 10.6028/NBS.NSRDS.36 Stafford, 1989, Interfacial properties and critical micelle concentration of lysophospholipids, Biochemistry, 28, 5113, 10.1021/bi00438a031 Matsuki, 2007, Thermotropic and barotropic phase transitions in bilayer membranes of ether-linked phospholipids with varying alkyl chain lengths, Biochim Biophys Acta, 1768, 479, 10.1016/j.bbamem.2006.10.005 Leidy, 2006, Domain-induced activation of human phospholipase A2 type IIA: local versus global lipid composition, Biophys J, 90, 3165, 10.1529/biophysj.105.070987 Kraske, 2001, Effects of cholesterol and temperature on the permeability of dimyristoylphosphatidylcholine bilayers near the chain melting phase transition, Biochim Biophys Acta, 1514, 159, 10.1016/S0005-2736(01)00379-0 Mayer, 2000, Designing liposomal anticancer drug formulations for specific therapeutic applications, J Liposome Res, 10, 99, 10.3109/08982100009029381 Inoue, 2001, Effect of fatty acids on phase behavior of hydrated dipalmitoylphosphatidylcholine bilayer: saturated versus unsaturated fatty acids, Chem Phys Lipids, 109, 117, 10.1016/S0009-3084(00)00170-5 Vattulainen, 2005, Diffusion in membranes Lohner, 2009, New strategies for novel antibiotics: peptides targeting bacterial cell membranes, Gen Physiol Biophys, 28, 105, 10.4149/gpb_2009_02_105 Bechinger, 2011, Insights into the mechanisms of action of host defence peptides from biophysical and structural investigations, J Pept Sci, 17, 306, 10.1002/psc.1343 Teixeira, 2012, Role of lipids in the interaction of antimicrobial peptides with membranes, Prog Lipid Res, 51, 149, 10.1016/j.plipres.2011.12.005 Jones, 1999, Surfactants in membrane solubilisation, Int J Pharm, 177, 137, 10.1016/S0378-5173(98)00345-7 Garidel, 2007, Membranolytic activity of bile salts: influence of biological membrane properties and composition, Molecules, 12, 2292, 10.3390/12102292 Heerklotz, 2008, Interactions of surfactants with lipid membranes, Q Rev Biophys, 41, 205, 10.1017/S0033583508004721 Israelachvili, 2010 Cantor, 1999, Lipid composition and the lateral pressure profile in bilayers, Biophys J, 76, 2625, 10.1016/S0006-3495(99)77415-1 Fuller, 2001, The influence of lysolipids on the spontaneous curvature and bending elasticity of phospholipid membranes, Biophys J, 81, 243, 10.1016/S0006-3495(01)75695-0 Marrink, 2009, Lipids on the move: simulations of membrane pores, domains, stalks and curves, Biochim Biophys Acta, 1788, 149, 10.1016/j.bbamem.2008.10.006 Bechinger, 1999, The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy, Biochim Biophys Acta, 1462, 157, 10.1016/S0005-2736(99)00205-9 Mihajlovic, 2010, Antimicrobial peptides in toroidal and cylindrical pores, Biochim Biophys Acta, 1798, 1485, 10.1016/j.bbamem.2010.04.004 Sengupta, 2008, Toroidal pores formed by antimicrobial peptides show significant disorder, Biochim Biophys Acta, 1778, 2308, 10.1016/j.bbamem.2008.06.007 Yoneyama, 2009, Peptide–lipid huge toroidal pore, a new antimicrobial mechanism mediated by a lactococcal bacteriocin, lacticin Q, Antimicrob Agents Chemother, 53, 3211, 10.1128/AAC.00209-09 Matsuzaki, 1998, Mechanism of synergism between antimicrobial peptides Magainin 2 and PGLa, Biochemistry, 37, 15144, 10.1021/bi9811617 Bechinger, 2006, Detergent-like actions of linear amphipathic cationic antimicrobial peptides, Biochim Biophys Acta, 1758, 1529, 10.1016/j.bbamem.2006.07.001 Campelo, 2007, Model for curvature-driven pearling instability in membranes, Phys Rev Lett, 99, 088101, 10.1103/PhysRevLett.99.088101 Domanov, 2006, Antimicrobial peptides temporins B and L induce formation of tubular lipid protrusions from supported phospholipid bilayers, Biophys J, 91, 4427, 10.1529/biophysj.106.091702 Caccin, 2009, Neurotoxicity of inverted-cone shaped lipids, Neurotoxicology, 30, 174, 10.1016/j.neuro.2008.11.013 Kamp, 1995, Fatty acid flip-flop in phospholipid bilayers is extremely fast, Biochemistry, 34, 11928, 10.1021/bi00037a034 Haest, 1981, Selective removal of lipids from the outer membrane layer of human erythrocytes without hemolysis. Consequences for bilayer stability and cell shape, Biochim Biophys Acta, 649, 701, 10.1016/0005-2736(81)90174-7 Gijon, 1999, Regulation of arachidonic acid release and cytosolic phospholipase A2 activation, J Leukocyte Biol, 65, 330, 10.1002/jlb.65.3.330 Berk, 1999, Mechanisms of cellular uptake of long chain free fatty acids, Mol Cell Biochem, 192, 17, 10.1023/A:1006832001033 Lunn, 2006, The health effects of dietary unsaturated fatty acids, Nutr Bull, 31, 178, 10.1111/j.1467-3010.2006.00571.x Shimano, 2012, Novel qualitative aspects of tissue fatty acids related to metabolic regulation: lessons from Elovl6 knockout, Prog Lipid Res, 51, 267, 10.1016/j.plipres.2011.12.004 Little, 2012, The saturated fatty acid palmitate induces human monocytic cell toxicity toward neuronal cells: exploring a possible link between obesity-related metabolic impairments and neuroinflammation, J Alzheimers Dis, 30, S179, 10.3233/JAD-2011-111262 Lee, 2010, Modulation of pattern recognition receptor-mediated inflammation and risk of chronic diseases by dietary fatty acids, Nutr Rev, 68, 38, 10.1111/j.1753-4887.2009.00259.x Schwartz, 2010, Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation, Arterioscler, Thromb, Vasc Biol, 30, 802, 10.1161/ATVBAHA.109.201681 Nakamura, 2009, Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria, J Biol Chem, 284, 14809, 10.1074/jbc.M901488200 Riccardi, 2004, Dietary fat, insulin sensitivity and the metabolic syndrome, Clin Nutr, 23, 447, 10.1016/j.clnu.2004.02.006 Im, 2012, Omega-3 fatty acids in anti-inflammation (pro-resolution) and GPCRs, Prog Lipid Res, 51, 232, 10.1016/j.plipres.2012.02.003 Frasch, 2012, Emerging roles for lysophosphatidylserine in resolution of inflammation, Prog Lipid Res, 51, 199, 10.1016/j.plipres.2012.03.001 Mehta, 2005, Lysophosphatidylcholine: an enigmatic lysolipid, Am J Physiol Lung Cell Mol Physiol, 289, L174, 10.1152/ajplung.00165.2005 Choi, 2010, LPA receptors: subtypes and biological actions, Annu Rev Pharmacol Toxicol, 50, 157, 10.1146/annurev.pharmtox.010909.105753 Kabarowski, 2009, G2A and LPC: regulatory functions in immunity, Prostaglandins Other Lipid Mediat, 89, 73, 10.1016/j.prostaglandins.2009.04.007 Wang, 1999, Mammalian lysophospholipases, Biochim Biophys Acta, 1439, 1, 10.1016/S1388-1981(99)00063-3 Stafford, 1987, Lysophospholipids as biosurfactants, Colloids Surf, 30, 47, 10.1016/0166-6622(87)80203-2 Ye, 2008, Lysophospholipid signaling in the function and pathology of the reproductive system, Hum Reprod Update, 14, 519, 10.1093/humupd/dmn023 Rigoni, 2005, Equivalent effects of snake PLA2 neurotoxins and lysophospholipid-fatty acid mixtures, Science, 310, 1678, 10.1126/science.1120640 Wu, 1998, Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL, Arterioscler, Thromb, Vasc Biol, 18, 626, 10.1161/01.ATV.18.4.626 Murph, 2009, Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis, PLoS One, 4, e5583, 10.1371/journal.pone.0005583 Reman, 1969, Vandeene Ll, Eibl H, Westphal O. Studies on lysis of red cells and bimolecular lipid leaflets by synthetic lysolecithins, lecithins and structural analogs, Chem Phys Lipids, 3, 221, 10.1016/0009-3084(69)90014-0 Weltzien, 1979, Cytolytic and membrane-perturbing properties of lysophosphatidylcholine, Biochim Biophys Acta, 559, 259, 10.1016/0304-4157(79)90004-2 Lapre, 1992, Lytic effects of mixed micelles of fatty acids and bile acids, Am J Physiol, 263, G333 Andresen, 2005, Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue, J Med Chem, 48, 7305, 10.1021/jm049006f Traikia, 2005, Impact of exogenous lysolipids on sensitive and multidrug resistant K562 cells: 1H NMR studies, Chem-Biol Interact, 151, 83, 10.1016/j.cbi.2004.12.005 Hsieh, 2000, Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL, Atherosclerosis, 151, 481, 10.1016/S0021-9150(00)00453-6 Kong, 2000, Palmitate-induced apoptosis in cardiomyocytes is mediated through alterations in mitochondria: prevention by cyclosporin A, Biochim Biophys Acta, 1485, 45, 10.1016/S1388-1981(00)00028-7 Sparagna, 2000, A metabolic role for mitochondria in palmitate-induced cardiac myocyte apoptosis, Am J Physiol Heart Circ Physiol, 279, H2124, 10.1152/ajpheart.2000.279.5.H2124 van der Luit, 2002, Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis, J Biol Chem, 277, 39541, 10.1074/jbc.M203176200 Pardini, 2006, Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents, Chem-Biol Interact, 162, 89, 10.1016/j.cbi.2006.05.012 Sauer, 2000, Mechanism for the antitumor and anticachectic effects of n-3 fatty acids, Cancer Res, 60, 5289 Harris, 2003, Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma, Cancer, 97, 71, 10.1002/cncr.11055 Kong, 2009, Gamma-linolenic acid modulates the response of multidrug-resistant K562 leukemic cells to anticancer drugs, Toxicol in Vitro, 23, 634, 10.1016/j.tiv.2009.02.010 Das, 1998, Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites?, Prostaglandins, Leukotrienes Essent Fatty Acids, 58, 39, 10.1016/S0952-3278(98)90128-4 Davies, 1999, Effect of γ-linolenic acid on cellular uptake of structurally related anthracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell lines, Eur J Cancer, 35, 1534, 10.1016/S0959-8049(99)00181-1 Lund, 2009, Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands, J Med Chem, 52, 1540, 10.1021/jm801532e Lund, 2005, Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist, J Med Chem, 48, 7517, 10.1021/jm050891r Foged, 2007, Phospholipase A2 sensitive liposomes for delivery of small interfering RNA (siRNA), J Liposome Res, 17, 191, 10.1080/08982100701530373 Foged, 2007, Liposomes for phospholipase A(2) triggered siRNA release: preparation and in vitro test, Int J Pharm, 331, 160, 10.1016/j.ijpharm.2006.11.010 Marques, 2009, Firefly bioluminescence. a mechanistic approach of luciferase catalyzed reactions, IUBMB Life, 61, 6, 10.1002/iub.134 Mortimer, 1999, Cationic lipid-mediated transfection of cells in culture requires mitotic activity, Gene Ther, 6, 403, 10.1038/sj.gt.3300837 van Lummel, 2011, Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors, FASEB J, 25, 280, 10.1096/fj.10-163709